Nextage Therapeutics (Israel) Probability of Future Stock Price Finishing Under 68.11
| NXTG Stock | ILA 77.10 1.00 1.31% |
Nextage |
Nextage Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Nextage Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Nextage Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Nextage Therapeutics had very high historical volatility over the last 90 days | |
| Nextage Therapeutics has accumulated 1.11 M in total debt. Nextage Therapeutics has a current ratio of 0.43, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Nextage Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Nextage Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nextage Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nextage to invest in growth at high rates of return. When we think about Nextage Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 91 K. Net Loss for the year was (7.73 M) with profit before overhead, payroll, taxes, and interest of 16 K. | |
| Nextage Therapeutics has accumulated about 358 K in cash with (3.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.16. | |
| Roughly 82.0% of the company outstanding shares are owned by corporate insiders |
Nextage Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Nextage Stock often depends not only on the future outlook of the current and potential Nextage Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Nextage Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 26.1 M | |
| Short Long Term Debt | 202 K |
Nextage Therapeutics Technical Analysis
Nextage Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Nextage Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Nextage Therapeutics. In general, you should focus on analyzing Nextage Stock price patterns and their correlations with different microeconomic environments and drivers.
Nextage Therapeutics Predictive Forecast Models
Nextage Therapeutics' time-series forecasting models is one of many Nextage Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Nextage Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Nextage Therapeutics
Checking the ongoing alerts about Nextage Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Nextage Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Nextage Therapeutics had very high historical volatility over the last 90 days | |
| Nextage Therapeutics has accumulated 1.11 M in total debt. Nextage Therapeutics has a current ratio of 0.43, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Nextage Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Nextage Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nextage Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nextage to invest in growth at high rates of return. When we think about Nextage Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 91 K. Net Loss for the year was (7.73 M) with profit before overhead, payroll, taxes, and interest of 16 K. | |
| Nextage Therapeutics has accumulated about 358 K in cash with (3.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.16. | |
| Roughly 82.0% of the company outstanding shares are owned by corporate insiders |
Other Information on Investing in Nextage Stock
Nextage Therapeutics financial ratios help investors to determine whether Nextage Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nextage with respect to the benefits of owning Nextage Therapeutics security.